Daiichi Sankyo stops work on RA drug biosimilar for Japan
Japanese drug major Daiichi Sankyo (TYO: 4568) today announced that it has decided to discontinue the development of CHS-0214 in Japan, an investigational etanercept biosimilar in rheumatoid arthritis conducted with the US company, Coherus BioSciences.
Etancercept is the active ingredient of US biotech major Amgen’s (Nasdaq: AMGN) Enbrel, sales of which increased 11% to $5.96 billion for full-year 2016. However, in the first quarter of this year, sales decreased 15% to $1.18 billion due to the impact of competition from biosimilars which have been coming to the market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
| Headless Content Management with Blaze